Phase 2 Study of Selinexor and Bispecific Antibody for Treating Relapsed/Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Able to provide written consent to participate.
• Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Diagnosed with symptomatic multiple myeloma that has returned or not responded to at least four previous treatments, including specific types of drugs.
• Eligible to receive certain bispecific antibody therapies as per approved guidelines.
• Any previous side effects from bispecific antibody therapy must be resolved before starting Selinexor.
• Have measurable disease based on specific medical tests.
• Have adequate liver and kidney function as shown by recent lab tests.
• Have adequate blood cell counts.
• Women who can become pregnant must have a negative pregnancy test before starting treatment.
• All participants must agree to use effective birth control during the study and for five months after the last dose.
• Women must agree not to donate eggs, and men must agree not to donate sperm during the study and for 90 days after the last dose.

Exclusion Criteria

• Previously treated with Selinexor or similar drugs and did not respond.
• Have any uncontrolled medical conditions that could interfere with the study.
• Have an active infection requiring treatment within one week before starting the study.
• Pregnant or breastfeeding women.
• Have unstable heart conditions or recent heart attack.
• Have certain viral infections unless they are well-controlled.
• Have unresolved side effects from previous bispecific antibody treatment.
• Have digestive issues that prevent swallowing or absorbing the medication.
• Unable or unwilling to take supportive medications for side effects.
• Have any condition that could interfere with the study or giving consent.
• Have allergies to any required medications or treatments.
• Unwilling or unable to follow the study protocol.